{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:51:41Z","timestamp":1790009501111,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ensci.2021.100324","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T12:26:17Z","timestamp":1612268777000},"page":"100324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Saskia","family":"Bolz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thivyah","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Stolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kizina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ensci.2021.100324_bb0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Ther."},{"issue":"17","key":"10.1016\/j.ensci.2021.100324_bb0010","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of Long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.ensci.2021.100324_bb0015","doi-asserted-by":"crossref","first-page":"10275","DOI":"10.1073\/pnas.0805459105","article-title":"Structures of PD-1 with its ligands: sideways and dancing cheek to cheek","volume":"105","author":"Freeman","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ensci.2021.100324_bb0020","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.ensci.2021.100324_bb0025","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.ensci.2021.100324_bb0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1399-0039.2003.00136.x","article-title":"Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes","volume":"62","author":"Nielsen","year":"2003","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.ensci.2021.100324_bb0035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.ejhg.5201767","article-title":"Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus","volume":"15","author":"Velazquez-Cruz","year":"2007","journal-title":"Eur. J. Hum. Genet."},{"issue":"18","key":"10.1016\/j.ensci.2021.100324_bb0040","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ensci.2021.100324_bb0045","first-page":"185","article-title":"Management of Toxicities of Immune Checkpoint Inhibitors","volume":"44","author":"Horio","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"10.1016\/j.ensci.2021.100324_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"C","year":"2015","journal-title":"N Engl J Med 2"},{"issue":"14","key":"10.1016\/j.ensci.2021.100324_bb0055","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ensci.2021.100324_bb0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single Centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ensci.2021.100324_bb0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, Including a Case Series of Encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ensci.2021.100324_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.ensci.2021.100324_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"12","key":"10.1016\/j.ensci.2021.100324_bb0080","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ensci.2021.100324_bb0085","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.ensci.2021.100324_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ensci.2021.100324_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by Ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.ensci.2021.100324_bb0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ensci.2021.100324_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ensci.2021.100324_bb0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract. Neurol."},{"issue":"4","key":"10.1016\/j.ensci.2021.100324_bb0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ensci.2021.100324_bb0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced Guillain-Barre syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm. Venereol."},{"issue":"4","key":"10.1016\/j.ensci.2021.100324_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.ensci.2021.100324_bb0130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS demyelination after treatment with Nivolumab for melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.ensci.2021.100324_bb0135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"10.1016\/j.ensci.2021.100324_bb0140","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.ensci.2021.100324_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000773","article-title":"Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors","volume":"7","author":"Nowosielski","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ensci.2021.100324_bb0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation","volume":"6","author":"Chang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ensci.2021.100324_bb0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-444-63432-0.00023-2","article-title":"Autoimmune-mediated peripheral neuropathies and autoimmune pain","volume":"133","author":"Klein","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.ensci.2021.100324_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J. Immunother."},{"issue":"8","key":"10.1016\/j.ensci.2021.100324_bb0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ensci.2021.100324_bb0170","article-title":"Case reports of Pembrolizumab-induced acute inflammatory demyelinating polyneuropathy","volume":"10","author":"Manam","year":"2018","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ensci.2021.100324_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mayocpiqo.2017.07.004","article-title":"Brachial plexus neuritis associated with anti-programmed cell Death-1 antibodies: report of 2 cases","volume":"1","author":"Alhammad","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.ensci.2021.100324_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"5238","key":"10.1016\/j.ensci.2021.100324_bb0195","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ensci.2021.100324_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.ensci.2021.100324_bb0205","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing Spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650221000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650221000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:18:38Z","timestamp":1762503518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650221000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":39,"alternative-id":["S2405650221000162"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2021.100324","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-19760\/v1","asserted-by":"object"}]},"ISSN":["2405-6502"],"issn-type":[{"value":"2405-6502","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2021.100324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100324"}}